Dollinger index

Biocon Ltd.: Building a Biotech Powerhouse 525

Amylases
Cellulases

Esterases
Glucanases
Hemicellulases
Xylanases
Oxidases

Pectinases
Proteases
Tannase

Anti-Diabetic Agents

Anti-Hypertensive Agents

Anti-Inflammatory Agents

Antioxidants

Cardiovascular Agents

Digestive Aid Enzymes

Haemostatic Agents

Hepatoprotective Agents

Immunosuppressants

Nutraceuticals

Small Molecule Synthesis

Medicinal Chemistry

Library Synthesis

Solution Phase

Solid Phase

Custom Synthesis - GMP

Process Chemistry

Molecular Genetics

rDNA /cDNA/gDNA

Clinical Trials

Phases I – IV

Patient databases in select

disease segments (dia-

betes, oncology, lipidemia

and cardiovascular)

Clinical Studies

Bioavailability & Bio-equiva-

lence

Novel Biomarkers via

Proteomics & Data-mining

Products Services

Enzymes Biopharmaceuticals Custom Research Clinical Research

EXHIBIT 5 Biocon: Product and Service Offerings

SOURCE: Biocon Ltd. files

Revenue

% of total

revenue

Cost of

sales

Operating

income

% of total

operating

income

2005

20,560

12.58

10,269

10,291

16.61

2004

15,249

12.30

9,222

6,027

12.52

2005

127,621

78.12

82,465

45,156

72.90

2004

99,809

80.53

60,768

39,041

81.08

2005

317

0.20

985

(657)

(1.05)

2004

298

0.24

724

(391)

(0.83)

2005

14,860

9.10

7,697

7,152

11.54

2004

8,587

6.93

5,076

3,476

7.23

2005

163,358

101,416

61,942

2004

123,943

75,790

48,153

Enzymes Bio-pharma Total

SOURCE: Biocon Ltd. files.

Custom

Research

Clinical

Research

EXHIBIT 6 Segment-wise Profitabiltiy (U.S. $thousands)

——

——